Citations

Clear

9383 citation(s) found for "Thomas, PS".

Bladder Cancer, Version 3.2024
Flaig, Thomas W. , Abern, Michael, Agarwal, Neeraj , Bangs, Rick , Buyyounouski, Mark K. , Chang, Paul, Friedlander, Terence W. , Greenberg, Richard E. , Guru, Khurshid A. , Herr, Harry W., Hoffman‐Censits, Jean , Kaimakliotis, Hristos Z. , Kishan, Amar U. , Kundu, Shilajit , Lele, Subodh M. , Mamtani, Ronac , Michalski, Jeff M., Montgomery, Jeffrey S., Patterson, Anthony, Peyton, Charles C. , Preston, Mark A. , Sexton, Wade J. , Stewart, Tyler F. , Sundi, Debasish , Tollefson, Matthew K. , Wright, Jonathan L. , Cassara, Carly J., Gurski, Lisa A., Tollefson, Matthew, Spiess, Philippe E. , Agarwal, Neeraj , Chan, Kevin , Chang, Sam S. , Chang, Paul, Mian, Omar Y. , Parikh, Mamta , Plimack, Elizabeth R. , Richards, Kyle A. , Siefker-Radtke, Arlene Odelia , Tward, Jonathan D.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 16, 2024 | Volume: 22 | Issue: 4 | Pages: 216-225

10.6004/jnccn.2024.0024 | PMID 38754471 Get It

Bladder cancer, the sixth most common cancer in the United States, is most commonly of the urothelial carcinoma histologic subtype. The clinical spectrum of bladder cancer is divided into 3 categories that differ in prognosis, management, and therapeutic aims: (1) non–muscle-invasive bladder cancer (NMIBC); (2) muscle invasive, nonmetastatic disease; and (3) metastatic bladder cancer. These NCCN Guidelines Insights detail recent updates to the NCCN Guidelines for Bladder Cancer, including changes in the fifth edition of the WHO Classification of Tumours: Urinary and Male Genital Tumours and how the NCCN Guidelines aligned with these updates; new and emerging treatment options for bacillus Calmette-Guérin (BCG)–unresponsive NMIBC; and updates to systemic therapy recommendations for advanced or metastatic disease.
Cross-Sectional Associations of Peripheral Hearing, Brain Imaging, and Cognitive Performance With Speech-in-Noise Performance: The Aging and Cognitive Health Evaluation in Elders Brain Magnetic Resonance Imaging Ancillary Study
Jiang, Kening , Albert, Marilyn , Pankow, James S. , Pike, James Russell , Reed, Nicholas S. , Sharrett, A. Richey, Lin, Frank R. , Study, for the ACHIEVE Collaborative, Sanchez, Victoria A , Deal, Jennifer A , Pankow, James S , Pike, James R , Coresh, Josef , Couper, David , Gottesman, Rebecca F. , Hayden, Kathleen M. , Jack, Clifford R. , Knopman, David S. , Mosley, Thomas H. , Sharrett, A. Richey, Deal, Jennifer A. , Study, for the ACHIEVE Collaborative

Mayo Clinic

American Journal of Audiology | May 15, 2024 | Volume: 33 | Issue: 3 | Pages: 683-694

10.1044/2024_aja-23-00108 | PMID 38748919 Get It

Purpose: Population-based evidence in the interrelationships among hearing, brain structure, and cognition is limited. This study aims to investigate the cross-sectional associations of peripheral hearing, brain imaging measures, and cognitive function with speech-in-noise performance among older adults. Method: We studied 602 participants in the Aging and Cognitive Health Evaluation in Elders (ACHIEVE) brain magnetic resonance imaging (MRI) ancillary study, including 427 ACHIEVE baseline (2018–2020) participants with hearing loss and 175 Atherosclerosis Risk in Communities Neurocognitive Study Visit 6/7 (2016–2017/2018–2019) participants with normal hearing. Speech-in-noise performance, as outcome of interest, was assessed by the Quick Speech-in-Noise (QuickSIN) test (range: 0–30; higher = better). Predictors of interest included (a) peripheral hearing assessed by pure-tone audiometry; (b) brain imaging measures: structural MRI measures, white matter hyperintensities, and diffusion tensor imaging measures; and (c) cognitive performance assessed by a battery of 10 cognitive tests. All predictors were standardized to z scores. We estimated the differences in QuickSIN associated with every standard deviation ( SD ) worse in each predictor (peripheral hearing, brain imaging, and cognition) using multivariable-adjusted linear regression, adjusting for demographic variables, lifestyle, and disease factors (Model 1), and, additionally, for other predictors to assess independent associations (Model 2). Results: Participants were aged 70–84 years, 56% female, and 17% Black. Every SD worse in better-ear 4-frequency pure-tone average was associated with worse QuickSIN (−4.89, 95% confidence interval, CI [−5.57, −4.21]) when participants had peripheral hearing loss, independent of other predictors. Smaller temporal lobe volume was associated with worse QuickSIN, but the association was not independent of other predictors (−0.30, 95% CI [−0.86, 0.26]). Every SD worse in global cognitive performance was independently associated with worse QuickSIN (−0.90, 95% CI [−1.30, −0.50]). Conclusions: Peripheral hearing and cognitive performance are independently associated with speech-in-noise performance among dementia-free older adults. The ongoing ACHIEVE trial will elucidate the effect of a hearing intervention that includes amplification and auditory rehabilitation on speech-in-noise understanding in older adults. Supplemental Material: https://doi.org/10.23641/asha.25733679
GG-06 Single cell gene expression studies in lupus patient monocytes reveal novel patterns reflecting disease activity, interferon, and medical treatment
Jin, Zhongbo , Jensen, Mark A, Dorschner, Jessica M., Vsetecka, Danielle, Amin, Shreyasee , Ernste, Floranne C. , Osborn, Thomas G. , Moder, Kevin G., Chowdhary, Vaidehi , Fan, Wei, Jensen, Mark A, Makol, Ashima , Niewold, Timothy B.

Mayo Clinic

Genetics, Genomics and Epigenetics | May 14, 2024 | Volume: No volume available | Issue: No issue available | Pages: A30.1-A30

10.1136/lupus-2016-000179.58 Get It

Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models
Jain, Sonia , Griffith, Jessica I. , Porath, Kendra A. , Rathi, Sneha , Le, Jiayan , Pasa, Tugce I. , Decker, Paul A. , Gupta, Shiv K. , Hu, Zeng , Carlson, Brett L. , Feldsien, Thomas M. , Lefebvre, Didier R. , Eckel‐Passow, Jeanette E. , Reilly, Edward B. , Elmquist, William F. , Bakken, Katrina K , Burgenske, Danielle M , Feldsien, Thomas M , Lefebvre, Didier R , Vaubel, Rachael A , Eckel-Passow, Jeanette E , Reilly, Edward B , Elmquist, William F , Sarkaria, Jann N , Gupta, Shiv K , Pasa, Tugce I , Jain, Sonia , Decker, Paul A. , Bakken, Katrina K. , Burgenske, Danielle M. , Vaubel, Rachael A. , Sarkaria, Jann N.

Mayo Clinic

Clinical Cancer Research | May 14, 2024 | Volume: 30 | Issue: 15 | Pages: 3287-3297

10.1158/1078-0432.ccr-24-0426 | PMID 38743766 Get It

Abstract Purpose: Antibody-drug conjugates (ADC) are targeted therapies with robust efficacy in solid cancers, and there is intense interest in using EGFR-specific ADCs to target EGFR-amplified glioblastoma (GBM). Given GBM’s molecular heterogeneity, the bystander activity of ADCs may be important for determining treatment efficacy. In this study, the activity and toxicity of two EGFR-targeted ADCs with similar auristatin toxins, Losatuxizumab vedotin (ABBV-221) and Depatuxizumab mafodotin (Depatux-M), were compared in GBM patient-derived xenografts (PDX) and normal murine brain following direct infusion by convection-enhanced delivery (CED). Experimental Design: EGFRviii-amplified and non-amplified GBM PDXs were used to determine in vitro cytotoxicity, in vivo efficacy, and bystander activities of ABBV-221 and Depatux-M. Nontumor-bearing mice were used to evaluate the pharmacokinetics (PK) and toxicity of ADCs using LC-MS/MS and immunohistochemistry. Results: CED improved intracranial efficacy of Depatux-M and ABBV-221 in three EGFRviii-amplified GBM PDX models (Median survival: 125 to >300 days vs. 20–49 days with isotype control AB095). Both ADCs had comparable in vitro and in vivo efficacy. However, neuronal toxicity and CD68+ microglia/macrophage infiltration were significantly higher in brains infused with ABBV-221 with the cell-permeable monomethyl auristatin E (MMAE), compared with Depatux-M with the cell-impermeant monomethyl auristatin F. CED infusion of ABBV-221 into the brain or incubation of ABBV-221 with normal brain homogenate resulted in a significant release of MMAE, consistent with linker instability in the brain microenvironment. Conclusions: EGFR-targeting ADCs are promising therapeutic options for GBM when delivered intratumorally by CED. However, the linker and payload for the ADC must be carefully considered to maximize the therapeutic window.
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas
Bhansali, Rahul S. , Ellin, Fredrik , Relander, Thomas, Cao, Miao , Li, Wenrui , Long, Qi , Ganesan, Nivetha , Stuver, Robert , Wudhikarn, Kitsada, Sokol, Lubomir, Duan, Frank, Pullarkat, Priyanka, Mehta–Shah, Neha , Ruiz, Miguel , Brammer, Jonathan E. , Prakash, Rishab, Iyer, Swaminathan P. , Major, Ajay , Smith, Sonali M. , Goldin, Caroline, Haverkos, Bradley M. , Zhuang, Tony , Allen, Pamela B. , Toama, Wael , Janakiram, Murali , Brooks, Taylor , Jagadeesh, Deepa, Hariharan, Nisha , Goodman, Aaron M. , Hartman, Gabrielle, Fayyaz, Fatima , Gerson, James N. , Svoboda, Jakub , Long, Qi , Wudhikarn, Kitsada , Hwang, Steven R , Bennani, N Nora , Saeed, Hayder , Porcu, Pierluigi , Mehta-Shah, Neha , Zain, Jasmine , Olszewski, Adam J , Smith, Sonali M , Haverkos, Bradley M , Hu, Bei , Zhuang, Tony Z , Allen, Pamela Blair , Toama, Wael , Brooks, Taylor R , Ghione, Paola , Fayyaz, Fatima , Rhodes, Joanna , Chong, Elise A , Barta, Stefan K , Major, Ajay , Janakiram, Murali , Bhansali, Rahul S , Stuver, Robert , Horwitz, Steven M. , Hwang, Steven R. , Bennani, N. Nora , Chavez, Julio C , Olszewski, Adam J. , Riedell, Peter A. , Hu, Bei , Jagadeesh, Deepa , Hariharan, Nisha, Ghione, Paola , Rhodes, Joanna , Chong, Elise A. , Landsburg, Daniel J. , Nasta, Sunita , Schuster, Stephen J. , Jerkeman, Mats

Mayo Clinic

Blood Advances | May 13, 2024 | Volume: 8 | Issue: 13 | Pages: 3507-3518

10.1182/bloodadvances.2024012800 | PMID 38739715 Get It

Abstract Little is known about risk factors for central nervous system (CNS) relapse in mature T-cell and natural killer cell neoplasms (MTNKNs). We aimed to describe the clinical epidemiology of CNS relapse in patients with MTNKN and developed the CNS relapse In T-cell lymphoma Index (CITI) to predict patients at the highest risk of CNS relapse. We reviewed data from 135 patients with MTNKN and CNS relapse from 19 North American institutions. After exclusion of leukemic and most cutaneous forms of MTNKNs, patients were pooled with non-CNS relapse control patients from a single institution to create a CNS relapse–enriched training set. Using a complete case analysis (n = 182), including 91 with CNS relapse, we applied a least absolute shrinkage and selection operator Cox regression model to select weighted clinicopathologic variables for the CITI score, which we validated in an external cohort from the Swedish Lymphoma Registry (n = 566). CNS relapse was most frequently observed in patients with peripheral T-cell lymphoma, not otherwise specified (25%). Median time to CNS relapse and median overall survival after CNS relapse were 8.0 and 4.7 months, respectively. We calculated unique CITI risk scores for individual training set patients and stratified them into risk terciles. Validation set patients with low-risk (n = 158) and high-risk (n = 188) CITI scores had a 10-year cumulative risk of CNS relapse of 2.2% and 13.4%, respectively (hazard ratio, 5.24; 95% confidence interval, 1.50-18.26; P = .018). We developed an open-access web-based CITI calculator (https://redcap.link/citicalc) to provide an easy tool for clinical practice. The CITI score is a validated model to predict patients with MTNKN at the highest risk of developing CNS relapse.
Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials
Shah, Sanjiv J, Borlaug, Barry A. , Butler, Javed , Davies, Melanie J. , Kitzman, Dalane W. , Petrie, Mark C. , Verma, Subodh, Patel, Shachi, Einfeldt, Mette Nygaard , Jensen, Thomas, Rasmussen, Søren, Ben‐Gal, Tuvia , Kosiborod, Mikhail , Borlaug, Barry A , Butler, Javed , Asleh, Rabea , Kosiborod, Mikhail N , Petrie, Mark C , Shah, Sanjiv J , Sharma, Kavita , Verma, Subodh , Chinnakondepalli, Khaja , Asleh, Rabea , Gal, Tuvia Ben

Mayo Clinic

European Heart Journal | May 13, 2024 | Volume: 45 | Issue: 35 | Pages: 3254-3269

10.1093/eurheartj/ehae322 | PMID 38739118 Get It

Abstract Background and Aims In the STEP-HFpEF trial programme, treatment with semaglutide resulted in multiple beneficial effects in patients with obesity-related heart failure with preserved ejection fraction (HFpEF). Efficacy may vary according to baseline diuretic use, and semaglutide treatment could modify diuretic dose. Methods In this pre-specified analysis of pooled data from the STEP-HFpEF and STEP-HFpEF-DM trials (n = 1145), which randomized participants with HFpEF and body mass index ≥ 30 kg/m2 to once weekly semaglutide 2.4 mg or placebo for 52 weeks, we examined whether efficacy and safety endpoints differed by baseline diuretic use, as well as the effect of semaglutide on loop diuretic use and dose changes over the 52-week treatment period. Results At baseline, across no diuretic (n = 220), non-loop diuretic only (n = 223), and loop diuretic [<40 (n = 219), 40 (n = 309), and >40 (n = 174) mg/day furosemide equivalents] groups, there was progressively higher prevalence of hypertension and atrial fibrillation; and greater severity of obesity and heart failure. Over 52 weeks of treatment, semaglutide had a consistent beneficial effect on change in body weight across diuretic use categories (adjusted mean difference vs. placebo ranged from −8.8% [95% confidence interval (CI) −10.3, −6.3] to −6.9% [95% CI −9.1, −4.7] from no diuretics to the highest loop diuretic dose category; interaction P = .39). Kansas City Cardiomyopathy Questionnaire clinical summary score improvement was greater in patients on loop diuretics compared to those not on loop diuretics (adjusted mean difference vs. placebo: +9.3 [6.5; 12.1] vs. +4.7 points [1.3, 8.2]; P = .042). Semaglutide had consistent beneficial effects on all secondary efficacy endpoints (including 6 min walk distance) across diuretic subgroups (interaction P = .24–.92). Safety also favoured semaglutide vs. placebo across the diuretic subgroups. From baseline to 52 weeks, loop diuretic dose decreased by 17% in the semaglutide group vs. a 2.4% increase in the placebo group (P < .0001). Semaglutide (vs. placebo) was more likely to result in loop diuretic dose reduction (odds ratio [OR] 2.67 [95% CI 1.70, 4.18]) and less likely dose increase (OR 0.35 [95% CI 0.23, 0.53]; P < .001 for both) from baseline to 52 weeks. Conclusions In patients with obesity-related HFpEF, semaglutide improved heart failure-related symptoms and physical limitations across diuretic use subgroups, with more pronounced benefits among patients receiving loop diuretics at baseline. Reductions in weight and improvements in exercise function with semaglutide vs. placebo were consistent in all diuretic use categories. Semaglutide also led to a reduction in loop diuretic use and dose between baseline and 52 weeks. Clinical Trial Registration NCT04788511 and NCT04916470.
Outcomes of mechanical thrombectomy in anticoagulated patients with acute distal and medium vessel stroke
Salim, Hamza , Musmar, Basel , Adeeb, Nimer , Yedavalli, Vivek , Lakhani, Dhairya A. , Grewal, Sahibjot , Henninger, Nils , Sundararajan, Sri Hari , Khalife, Jane , Tan, Benjamin Yong‐Qiang , Regenhardt, Robert W. , Heit, Jeremy J. , Cancelliere, Nicole M , Rouchaud, Aymeric , Sheth, Sunil G. , Puri, Ajit S , Dyzmann, Christian , Colasurdo, Marco , Barreau, Xavier , Filipe, João Pedro , Abdalkader, Mohamad , Marotta, Thomas R. , Spears, Julian , Biswas, Arundhati , Clarençon, Frédéric , Varela, Ricardo , Baker, Amanda , Essibayi, Muhammed Amir , Altschul, David , Gonzalez, Nestor R. , Möhlenbruch, Markus , Costalat, Vincent , Gory, Benjamin , Stracke, Christian Paul , Shaikh, Hamza , Liebeskind, David S. , Alexandre, Andrea , Tancredi, Illario , Faizy, Tobias D. , Kalsoum, Erwah , Lubicz, Boris , Patel, Aman B. , Guenego, Adrien , Investigators, for the MAD MT, Valente, Iacopo , Hsieh, Cheng‐Yang , Lakhani, Dhairya , Scarcia, Luca , Regenhardt, Robert W , Fiehler, Jens , Alexandru Radu, Răzvan , Klein, Piers , Ota, Takahiro , Jabbour, Pascal , Nguyen, Thanh N , Essibayi, Muhammed Amir , Gonzalez, Nestor R , Möhlenbruch, Markus A , Liebeskind, David S. , Heit, Jeremy J , Altschul, David J , Musmar, Basel , Salim, Hamza , Yedavalli, Vivek S , Cancelliere, Nicole M , Rouchaud, Aymeric , Colasurdo, Marco , Henninger, Nils , Tan, Benjamin Yq , Alexandre, Andrea M , Varela, Ricardo , Naamani, Kareem El , Kühn, Anna Luisa , Ghozy, Sherief , Bernstock, Joshua D. , Fiehler, Jens , Sheth, Sunil, Renieri, Leonardo , Harker, Pablo , Radu, Răzvan Alexandru , Klein, Piers , Mowla, Ashkan , Jabbour, Pascal , Siegler, James E. , Nguyen, Thanh N. , Baker, Amanda, Aziz‐Sultan, Mohammad Ali , Hecker, Constantin , Pedicelli, Alessandro , Mendes Pereira, Vitor , Dmytriw, Adam A.

Mayo Clinic

European Stroke Journal | May 10, 2024 | Volume: 9 | Issue: 4 | Pages: 896-906

10.1177/23969873241249295 | PMID 38726983 Get It

Abstract Background: Stroke remains a major health concern globally, with oral anticoagulants widely prescribed for stroke prevention. The efficacy and safety of mechanical thrombectomy (MT) in anticoagulated patients with distal medium vessel occlusions (DMVO) are not well understood. Methods: This retrospective analysis involved 1282 acute ischemic stroke (AIS) patients who underwent MT in 37 centers across North America, Asia, and Europe from September 2017 to July 2023. Data on demographics, clinical presentation, treatment specifics, and outcomes were collected. The primary outcomes were functional outcomes at 90 days post-MT, measured by modified Rankin Scale (mRS) scores. Secondary outcomes included reperfusion rates, mortality, and hemorrhagic complications. Results: Of the patients, 223 (34%) were on anticoagulation therapy. Anticoagulated patients were older (median age 78 vs 74 years; p < 0.001) and had a higher prevalence of atrial fibrillation (77% vs 26%; p < 0.001). Their baseline National Institutes of Health Stroke Scale (NIHSS) scores were also higher (median 12 vs 9; p = 0.002). Before propensity score matching (PSM), anticoagulated patients had similar rates of favorable 90-day outcomes (mRS 0–1: 30% vs 37%, p = 0.1; mRS 0–2: 47% vs 50%, p = 0.41) but higher mortality (26% vs 17%, p = 0.008). After PSM, there were no significant differences in outcomes between the two groups. Conclusion: Anticoagulated patients undergoing MT for AIS due to DMVO did not show significant differences in 90-day mRS outcomes, reperfusion, or hemorrhage compared to non-anticoagulated patients after adjustment for covariates.
Systemic inflammation during midlife and cognitive change over 20 years
Walker, Keenan A. , Gottesman, Rebecca F. , Wu, Aozhou , Gross, Alden L. , Selvin, Elizabeth , Windham, B. Gwen , Selvin, Elizabeth , Selvin, Elizabeth , Gottesman, Rebecca F , Walker, Keenan A , Knopman, David S. , Mosley, Thomas H.

Mayo Clinic

Neurology | May 9, 2024 | Volume: 92 | Issue: 11 | Pages: No page available

10.1212/wnl.0000000000007094 | PMID 30760633 Get It

Exposure to hyperoxemia and mortality in cardiac intensive care unit patients
Alviar, Carlos L. , Metkus, Thomas S. , Miller, P. Elliott , Jentzer, Jacob C. , Diepen, Sean van , Kashani, Kianoush

Mayo Clinic

European Heart Journal: Acute Cardiovascular Care | May 9, 2024 | Volume: 13 | Issue: Supplement_1 | Pages: No page available

10.1093/ehjacc/zuae036.138 Get It

Abstract Funding Acknowledgements None. Background Hyperoxemia (a high PaO2, i.e. >200-300 mmHg) has been associated with adverse outcomes in general critical care settings as well as in acute cardiovascular care conditions. The association between hyperoxemia and mortality has not been characterized in the heterogeneous population admitted to the cardiac intensive care unit (CICU). We aimed to examine the association between hyperoxemia on CICU admission with in-hospital mortality. Methods We retrospectively analyzed Mayo Clinic CICU patients from January 2007 to April 2018. PaO2 closest on admission was analyzed as a continuous variable (per 100 mmHg) and categorized as: 60-100 mmHg (51.9%), 101-150 mmHg (28.6%), 151-200 mmHg (10.6%), 201-300 mmHg (6.4%), and >300 mmHg (2.5%). Those without PaO2 on admission and those with hypoxemia were excluded. The primary outcome was all-cause in-hospital mortality evaluated using logistic regression, after adjusting for age, Charlson Comorbidity Index, M-CARS, and use of IMV and NIPPV. Results A total of 3,368 patients were included (median 70.3 years, 39.4% women). Admission diagnoses included ACS (37.0%, with 19.8% STEMI), HF (67.8%), shock (33.0%) and cardiac arrest (25.3%). Median admission PaO2 was 99 (IQR 78, 136) mmHg, with no difference in median PaO2 between hospital survivors and inpatient deaths (99 versus 98, p = 0.38). A J-shaped relationship was observed between admission PaO2 and in-hospital mortality (Figure A), with slightly higher mortality below 100 mmHg and incrementally higher mortality above this threshold (esp. at >200 mmHg). The incremental association between higher PaO2 and mortality (adjusted OR 1.17 per 100 mmHg higher, 95% CI 1.01-1.34, P = 0.03) was focused in the highest PaO2 group (i.e., >300 mmHg; Figure B). Conclusion Hyperoxia (esp. PaO2 >300 mmHg) on CICU admission is associated with increased in-hospital mortality, demonstrating a J-shaped association with an inflection point of lowest mortality around 100 mmHg. Further studies are warranted to assess if specific oxygen targets influence outcomes in critically ill cardiac patients.
Cardiac biomarkers for diagnosing Takotsubo syndrome
Schweiger, Victor , Vece, Davide Di , Cammann, Victoria L. , Koleva, Iva, Würdinger, Michael , Gilhofer, Thomas , Rajman, Katja, Szawan, Konrad A. , Niederseer, David , Gili, Sebastiano , Franke, Jennifer , Meder, Benjamin , Knorr, Maike, Jansen, Thomas , Bruno, Francesco , Filippo, Ovidio De , Stefanini, Giulio , Wańha, Wojciech , Lewinski, Dirk von , Burgdorf, Christof , Kherad, Behrouz , Tschöpe, Carsten , Sarcon, Annahita, Shinbane, Jerold S., Rajan, Lawrence, Michels, Guido, Pfister, Roman , Jacobshagen, Claudius, Karakas, Mahir , Pott, Alexander , Meyer, Philippe , Roffi, Marco , Wolfrum, Mathias , Fischer, Thomas, Vasankari, Tuija , Dworakowski, Rafał , MacCarthy, Philip , Osswald, Stefan , Galiuto, Leonarda , Chan, Christina , Bridgman, Paul , Beug, Daniel , Gilyarova, Ekaterina, Poledníková, Karolína, Massoomi, Michael , Carrilho‐Ferreira, Pedro , Hauck, Christian , Paolini, Carla , Bilato, Claudio , Kobayashi, Yoshio , Ishibashi, Iwao, Himi, Toshiharu, Din, Jehangir , Rihal, Charanjit S. , Jörg, Lucas, Rickli, Hans , Böhm, Michael , Pinto, Fausto J. , Widimský, Petr , Felix, Stephan B. , Rottbauer, Wolfgang , Budnik, Monika , Opolski, Grzegorz , Kong, William , Dalakoti, Mayank , Imori, Yoichi , Münzel, Thomas , Lüscher, Thomas F. , Ghadri, Jelena R. , Templin, Christian , Citro, Rodolfo , Vecchione, Carmine , Bossone, Eduardo , Meder, Benjamin , Bruno, Francesco , De Filippo, Ovidio , Campo, Gianluca , von Lewinski, Dirk , Tschöpe, Carsten , Pfister, Roman , Koenig, Wolfgang , Meyer, Philippe , Banning, Adrian , Kobza, Richard , Galiuto, Leonarda , Lairez, Olivier , Gilyarov, Mikhail , Akin, Ibrahim , Ukena, Christian , Hauck, Christian , Paolini, Carla , Bilato, Claudio , Böhm, Michael , Widimský, Petr , Rottbauer, Wolfgang , Schunkert, Heribert , Thiele, Holger , Bauersachs, Johann , Di Mario, Carlo , Bax, Jeroen J , Templin, Christian , Koleva, Iva, Citro, Rodolfo , Vecchione, Carmine , Bossone, Eduardo , Neuhaus, Michael, Jaguszewski, Miłosz , Noutsias, Michel , D’Ascenzo, Fabrizio , Campo, Gianluca , Raposeiras‐Roubín, Sergio , Dichtl, Wolfgang , Cuneo, Alessandro , Köenig, Wolfgang , Banning, Adrian , Cuculi, Florim , Kobza, Richard , Airaksinen, Juhani , Napp, L. Christian , Kaiser, Christoph A. , Delmas, Clément , Lairez, Olivier , Shilova, Alexandra S. , El‐Battrawy, Ibrahim , Toušek, Petr , Winchester, David E. , Gałuszka, Jan , Ukena, Christian , Poglajen, Gregor , Kato, Ken , Al‐Shammari, Ali Saad , Prasad, Abhiram , Rihal, Charanjit S. , Liu, Kan , Schulze, Paul Christian , Bianco, Matteo , Pestana, Gonçalo , Nguyen, Thanh Ha Tuan , Maier, Lars S. , Braun-Dullaeus, Ruediger Christian , Hasenfuß, Gerd , Pieske, Burkert , Horowitz, John D. , Mario, Carlo Di , Bax, Jeroen J. , Crea, Filippo , Ruschitzka, Frank T.

Mayo Clinic

European Heart Journal | May 8, 2024 | Volume: 45 | Issue: 25 | Pages: 2254-2258

10.1093/eurheartj/ehae231 | PMID 38717630 Get It